NEW YORK (GenomeWeb News) — Promega has expanded its equity stake in Aussie RNAi company Benitec by buying 1.8 million ordinary shares at AU$.105 apiece ($.09), or $158,000, Benitec said today.
 
The deal, which is a 20-percent discount from the average trading price of Benitec shares over the past 60 days, follows the conversion of a year-old promissory note and increases Promega’s stake in the Australian company to 6.15 percent.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.